A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

NCT04826341 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

NIH

Sponsor class

Conditions

HRD Cancer
SCLC
Advanced Solid Tumors

Interventions

DRUG: Berzosertib
DRUG: Sacituzumab Govitecan

Sponsor

National Cancer Institute (NCI)